When most of us think of investing in stocks, we think of the potential gains -- or unfortunately, in some cases, losses -- that might follow. A particular stock will rise or fall, and we'll benefit or lose.
Abbott's Diagnostics arm is expected to have been driven by the widespread adoption of its top-tier systems and high testing demand in the fourth quarter.
Evaluate the expected performance of Abbott (ABT) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.
Abbott Laboratories will report earnings pre-market on January 22, with an earnings consensus of $1.04 per share. Abbott continues to execute growth businesses with excellent marketing and distribution, allowing them to scale faster and farther than competitors. On the basis of favorable trends, mitigated risks, and earnings expectations, I maintain my buy rating at a price target of $133.90.
In the latest trading session, Abbott (ABT) closed at $113.04, marking a -0.69% move from the previous day.
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Here is how Abbott (ABT) and Acurx Pharmaceuticals, Inc. (ACXP) have performed compared to their sector so far this year.
Want some solid dividend growth stocks with incredible track records of increasing their payouts? Here's a list of stocks that have been raising their dividend payments consistently for more than 50 consecutive years.
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Here, we discuss five stocks that are likely to generate better than the market, driven by strong demand for existing products and the addition of innovative new devices.